Drug-durg Interaction of RAY1225 With Warfarin, Atorvastatin, Metformin and Digoxin

Phase 1 Active not recruiting 32 enrolled Guangdong Raynovent Biotech Co., Ltd

NaSingle-groupOpen-labelBasic science

The drug-drug interaction study had been designed to investigate the effect of RAY1225 on the pharmacokinetics of digoxin, Rosuvastatin and

Evaluation	Drug	Modality	Dose	Route
Subject	Atorvastatin	Small molecule	20 mg	Oral
Subject	Digoxin	Other / unclassified	0.25 mg	Oral
Subject	Metformin	Small molecule	500 mg	Oral
Subject	RAY1225	Unknown	6 mg	Subcutaneous
Subject	Warfarin	Small molecule	10 mg	Oral